Skip to main content
Nature Communications logoLink to Nature Communications
. 2021 Nov 2;12:6431. doi: 10.1038/s41467-021-26548-6

Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein

Min Thura 1,#, Abdul Qader Al-Aidaroos 1,#, Abhishek Gupta 1, Cheng Ean Chee 2, Soo Chin Lee 2, Kam Man Hui 3, Jie Li 1, Yeoh Khay Guan 4, Wei Peng Yong 2, Jimmy So 5, Wee Joo Chng 2, Chin Hin Ng 2, Jianbiao Zhou 2, Ling Zhi Wang 6, John Shyi Peng Yuen 7, Henry Sun Sien Ho 7, Sim Mei Yi 7, Edmund Chiong 5, Su Pin Choo 8, Joanne Ngeow 1,8,9, Matthew Chau Hsien Ng 8, Clarinda Chua 8, Eugene Shen Ann Yeo 10, Iain Bee Huat Tan 8, Joel Xuan En Sng 1, Nicholas Yan Zhi Tan 1, Jean Paul Thiery 1, Boon Cher Goh 2, Qi Zeng 1,11,
PMCID: PMC8564534  PMID: 34728638

Correction to: Nature Communications 10.1038/s41467-019-10127-x, published online 06 June 2019.

In this article the funding from ‘Open Fund-Individual Research Grant (OF-IRG), National Medical Research Council (NMRC) Singapore with the project ID of NMRC/OFIRG/0053/2017’ was omitted.


Articles from Nature Communications are provided here courtesy of Nature Publishing Group

RESOURCES